Devonian Health Group, Inc. ( (TSE:GSD) ) has issued an update.
Devonian Health Group Inc. announced positive in vivo results from a study of Thykamine™ on gene expression associated with fibrosis. The study demonstrated statistically significant downregulation of genes linked to inflammation and fibrosis, suggesting that Thykamine™ may have beneficial effects as an anti-fibrotic medication across various chronic diseases affecting multiple organs. This advancement could potentially enhance the company’s market position in treating inflammatory and fibrotic diseases.
More about Devonian Health Group, Inc.
Devonian Health Group Inc. is a clinical stage company focused on developing unique solutions for inflammatory diseases. The company is involved in the pharmaceutical industry, with its primary product being Thykamine™, which is targeted at addressing inflammation and potentially fibrosis-related conditions.
YTD Price Performance: 25.00%
Average Trading Volume: 27,466
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$29.64M
Learn more about GSD stock on TipRanks’ Stock Analysis page.